drugset / Trial / NCT02892812

A Phase I Clinical Trial of a 13-valent Pneumococcal Conjugate Vaccine and 14-valent Pneumococcal Conjugate Vaccine in Adults

NCT02892812

Phase 1 Completed 63 enrolled LG Life Sciences
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of LBVE013 (Pneumococcal 13-valent conjugate vaccine \[diphtheria CRM197 protein\]) or LBVE014 (Pneumococcal 14-valent conjugate vaccine \[diphtheria CRM197 protein\]) in healthy adults.

Timeline

Start
2016-09
Primary completion
2016-11
Completion
2016-11

Drugs

EvaluationDrugModalityDoseRoute
Subject LBVE013 Vaccine Intramuscular
Subject LBVE014 Vaccine Intramuscular
Subject Prevnar 13 Vaccine Intramuscular